AI assistant
Quantum Genomics Regulatory Filings 2019
1617_iss_2019-12-16_b0f8197b-4d1d-4cf6-a5e0-b2b6abfb973b.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Quantum Genomics to Participate in Biotech Showcase 2020
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces its participation in Biotech Showcase 2020 in San Francisco, being held on January 13-15, 2020, in parallel to the annual J.P. Morgan Healthcare Conference.
On this occasion, Quantum Genomics Management team will present the latest developments of the company and will meet with both investors and pharmaceutical firms.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn
Contact information
| Quantum Genomics | |
|---|---|
| Jean-Philippe Milon | Marc Karako |
| CEO | CFO - Investor Relations |
| +33 (0)1 85 34 77 70 [email protected] | +33 (0)1 85 34 77 70 [email protected] |
| So Bang (Europe) | |
| Nathalie Boumendil | Samuel Beaupain |
| Financial Communications | Media Relations and Scientific Communications |
| +33 (0)6 85 82 41 95 [email protected] | +33 (0)6 88 48 48 02 [email protected] |
| LifeSci (USA) | |
| Dan Ferry | Mike Tattory |
| Financial Communications | Media Relations and Scientific Communications |
| +1 (617) 535-7746 [email protected] | +55 11 3573 6316 [email protected] |